Rapid Dose Therapeutics

Rapid Dose Therapeutics (RDTCF) extended its agreement with an international partner to evaluate its NicStrip™ oral thin film nicotine delivery system. The seven-month extension is valued at $1.8M CAD. RDT filed for Health Canada approval for NicStrip™ in multiple dosages and initiated a clinical study comparing it to traditional cigarettes. Two patent applications were filed covering dissolvable and non-dissolvable formats. NicStrip™ targets adult consumers seeking smoke-free alternatives. Market trends show significant growth in nicotine pouches and other modern oral nicotine products.